Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V Rohto Premium is a multi-ingredient ophthalmic solution developed by Rohto Pharmaceutical, primarily marketed in Japan as an over-the-counter (OTC) treatment for severe eye fatigue and discomfort. The formulation contains 12 active ingredients designed to address various aspects of eye strain, including neostigmine methylsulfate for focus adjustment, vitamins (B6, E, and panthenol) for metabolic support, and anti-inflammatory agents like allantoin and dipotassium glycyrrhizinate. It is indicated for the relief of eye fatigue, blurred vision, conjunctival congestion, and itching caused by prolonged screen use or environmental stressors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on V Rohto Premium.